Laurence W. Lytton 13D and 13G filings for Cellectar Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-13 3:49 pm Sale | 2024-12-31 | 13G | Cellectar Biosciences, Inc. CLRB | Laurence W. Lytton | 3,955,470 8.800% | -434,499 (-9.90%) | Filing |
| 2024-11-14 1:26 pm Purchase | 2024-09-30 | 13G | Cellectar Biosciences, Inc. CLRB | Laurence W. Lytton | 4,389,969 9.990% | 1,109,791 (+33.83%) | Filing |
| 2024-02-14 3:23 pm Purchase | 2023-12-31 | 13G | Cellectar Biosciences, Inc. CLRB | Laurence W. Lytton | 3,280,178 9.990% | 1,395,105 (+74.01%) | Filing |
| 2023-12-07 5:15 pm Purchase | 2023-10-25 | 13G | Cellectar Biosciences, Inc. CLRB | Laurence W. Lytton | 1,885,073 9.990% | 1,885,073 (New Position) | Filing |